BROLUCIZUMAB

brolucizumab 6 mg/0.05 mL intraocular injection, 0.05 mL syringe
Manner of administration:Injection
General Schedule
Authority Required

Restriction

Indication: Subfoveal choroidal neovascularisation (CNV)
Treatment phase: Initial treatment

Restriction

Indication: Subfoveal choroidal neovascularisation (CNV)
Treatment phase: Continuing treatment
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 2 DPMQ: $995.71 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Beovu